Double-digit revenue growth in FY27
Management expects double-digit growth for FY27, driven by all segments including human, animal, and food.
ADVANCEDENZYMETECHNOLOGI / guidance tracker
Keep management guidance in view.
Advanced Enzyme Technologies · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
EBITDA margin to remain around 31%
Margins expected to be steady with possible 1-2% variability due to cost pressures.
New R&D center operational in H2 FY27
The new R&D center in Nashik will be fully operational in the second half of FY27, boosting product development capacity threefold.
EU approval for anti-inflammatory product expected in FY27
The product filed two years ago is anticipated to receive EU approval this year, providing exclusivity for 5-10 years.